New England Journal Of Medicine Publishes Results From A RELISTOR Phase 3 Clinical Study

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the publication of results from a pivotal phase 3 trial of RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection in the May 29, 2008 issue of the New England Journal of Medicine.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on June 1st, 2008